Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1+ Macrophages Regulates the Intestinal Cytokine Milieu

Total Page:16

File Type:pdf, Size:1020Kb

Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1+ Macrophages Regulates the Intestinal Cytokine Milieu Lysophosphatidic acid-mediated GPR35 signaling in CX3CR1+ macrophages regulates the intestinal cytokine milieu Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Berna Kaya aus der Türkei 2020 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Christoph Hess Prof. Dr. Jan Hendrik Niess PD Dr. Cristian Riedel Basel, 23.06.2020 Prof. Dr. Martin Spiess The Dean of Faculty of Science Table of Contents TABLE OF CONTENTS ABBREVIATIONS .................................................................................................................. IV ABSTRACT ........................................................................................................................... VII 1 INTRODUCTION ................................................................................................................. 1 1.1 The intestinal immune system ................................................................................... 1 1.1.1 Innate immunity in the intestine ............................................................................ 1 1.1.1.1 Intestinal epithelium....................................................................................... 2 1.1.1.2 Mononuclear phagocytes ............................................................................... 5 1.1.2 Host- and microbiota-derived metabolites ........................................................... 10 1.2 Inflammatory bowel diseases .................................................................................. 14 1.2.1 Host immune system and genetics ...................................................................... 15 1.2.2 Microbiome ........................................................................................................ 15 1.2.3 Diet and other environmental factors .................................................................. 16 1.2.4 Current therapy options ...................................................................................... 17 1.3 G protein-coupled receptor (GPR) 35 .................................................................... 19 1.4 Aims of the study ..................................................................................................... 22 2 METHODS ........................................................................................................................ 23 2.1 Human samples ....................................................................................................... 23 2.2 Animals .................................................................................................................... 25 2.2.1 Mouse lines ........................................................................................................ 25 2.2.2 Generation of Gpr35-IRES-tdTomato knock-in mice .......................................... 25 2.2.3 Construction of Gpr35-flox and -knockout (KO) mice ........................................ 27 2.2.4 Zebrafish lines .................................................................................................... 29 2.3 In vivo experiments .................................................................................................. 31 2.3.1 Dextran sodium sulfate-induced colitis mouse model .......................................... 31 2.3.2 Mouse endoscopy ............................................................................................... 31 2.3.3 Treatment of zebrafish with 2,4,6-Trinitrobenzenesulfonic acid .......................... 31 2.3.4 Treatment of zebrafish with antibiotics ............................................................... 32 2.3.5 Treatment of mice with antibiotics ...................................................................... 32 2.3.6 Challenging of mice with E. coli-CFP ................................................................. 32 2.3.7 Exposure of zebrafish with Vibrio anguillarum ................................................... 32 2.3.9 LPA treatment of zebrafish larvae for cytokine expression analysis .................... 33 2.3.8 In vivo macrophage migration assay in zebrafish ................................................ 33 2.4 Histology and imaging ............................................................................................. 33 2.4.1 Preparation of RNA probes for Gpr35b in zebrafish ........................................... 33 2.4.2 In situ hybridization for gpr35b in zebrafish ....................................................... 34 2.4.3 GPR35 staining on human biopsies and mouse tissues ........................................ 35 2.4.4 Hematoxylin-eosin (H&E) staining and histological scoring ............................... 36 2.4.5 Autotaxin staining of mouse colon ...................................................................... 36 2.4.6 Ex vivo imaging of mouse tissues ........................................................................ 36 2.5 Cell isolation ............................................................................................................ 37 III Table of Contents 2.6 Antibodies, cell staining, and flow cytometry ......................................................... 37 2.7 RNA extraction and quantitative PCR ................................................................... 40 2.8 RNA sequencing ...................................................................................................... 41 2.9 In vitro assays ........................................................................................................... 42 2.9.1 3’-5’-Cyclic adenosine monophosphate (cAMP) assay ....................................... 42 2.9.2 Mouse bone marrow-derived macrophages (BMDMs) ........................................ 43 2.9.3 Trans-well migration assay for mouse BMDMs .................................................. 43 2.9.4 Enzyme-linked immunosorbent assay (ELISA) for corticosterone ...................... 44 2.9.5 LPA ELISA using ex vivo colonic explants of DSS-treated mice ........................ 44 2.10 Western blot LPA- or LPS- treated BMDMs ....................................................... 44 2.11 Identification of GPR35T108M and TNF blocker response in IBD patients .......... 45 2.12 Statistical analysis.................................................................................................. 45 3 RESULTS ........................................................................................................................... 46 3.1 Colonic macrophages express GPR35 .................................................................... 46 3.1.1 Gpr35b is predominant in the intestine of zebrafish ............................................ 46 3.1.2 Gpr35 is expressed in the human and mouse gastrointestinal tract ...................... 48 3.1.3 Macrophages in the intestinal lamina propria are GPR35+ ................................... 48 3.1.4 GPR35+ and GPR35- colonic macrophages are transcriptionally distinct ............. 51 3.2 Regulation of GPR35 by the microbiota and intestinal inflammation .................. 52 3.2.1 Gpr35 expression is microbiota-dependent in zebrafish and mice ....................... 52 3.2.2 Intestinal inflammation elevates GPR35 expression in zebrafish and mice .......... 54 3.2.3 Bacterial infection or colonization induces GPR35 in the intestine ...................... 55 3.2.4 Increased number of GPR35+ cells in patients with ulcerative colitis .................. 56 3.3 Lysophosphatidic acid signaling depends on GPR35 in macrophages .................. 57 3.3.1 LPA inhibits the cAMP release in humanGPR35-transfected cells ...................... 57 3.3.2 LPA leads to GPR35-dependent Tnf induction in zebrafish ................................. 58 3.3.3 GPR35-deficiency leads to altered LPA signaling in BMDMs ............................ 59 3.3.4 LPA facilitates GPR35-dependent chemotaxis of macrophages........................... 63 3.4 Intestinal inflammation enhances Autotaxin and LPA production ....................... 64 3.5 Macrophage-expressed GPR35 is protective in DSS colitis mouse model ............. 67 3.5.1 GPR35-deficient mice have augmented DSS-induced colitis ............................... 67 3.5.2 Macrophage-specific GPR35 deletion leads to aggravated colitis ........................ 68 3.5.3 LPA attenuates DSS colitis in a macrophage-expressed GPR35 manner ............. 70 3.5.4 Gpr35ΔCx3cr1 mice have enhanced neutrophil infiltration during DSS colitis ........ 71 3.5.5 GPR35 deletion in macrophages causes reduced TNF production in colitis ......... 73 3.6 TNF attenuates colitis and induces corticosterone synthesis in Gpr35ΔCx3cr1 mice 74 3.6.1 TNF is protective in Gpr35ΔCx3cr1 mice during DSS colitis .................................. 74 3.6.2 TNF induces Cyp11b1 and corticosterone synthesis in Gpr35ΔCx3cr1 mice ........... 76 3.6.3 TNF does not influence DSS colitis severity in WT mice .................................... 77 3.7 GPR35T108M variant might correlate with TNF blocker responses in IBD ............ 78 4 DISCUSSION ..................................................................................................................... 79 4.1 Heterogeneous expression of GPR35 in intestinal lamina propria monocytes and macrophages .................................................................................................................
Recommended publications
  • Targeting Lysophosphatidic Acid in Cancer: the Issues in Moving from Bench to Bedside
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks cancers Review Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside Yan Xu Department of Obstetrics and Gynecology, Indiana University School of Medicine, 950 W. Walnut Street R2-E380, Indianapolis, IN 46202, USA; [email protected]; Tel.: +1-317-274-3972 Received: 28 August 2019; Accepted: 8 October 2019; Published: 10 October 2019 Abstract: Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications. Keywords: Autotaxin (ATX); ovarian cancer (OC); cancer stem cell (CSC); electrospray ionization tandem mass spectrometry (ESI-MS/MS); G-protein coupled receptor (GPCR); lipid phosphate phosphatase enzymes (LPPs); lysophosphatidic acid (LPA); phospholipase A2 enzymes (PLA2s); nuclear receptor peroxisome proliferator-activated receptor (PPAR); sphingosine-1 phosphate (S1P) 1.
    [Show full text]
  • Metabolite Sensing Gpcrs: Promising Therapeutic Targets for Cancer Treatment?
    cells Review Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? Jesús Cosín-Roger 1,*, Dolores Ortiz-Masia 2 , Maria Dolores Barrachina 3 and Sara Calatayud 3 1 Hospital Dr. Peset, Fundación para la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO, 46017 Valencia, Spain 2 Departament of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] 3 Departament of Pharmacology and CIBER, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] (M.D.B.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +34-963851234 Received: 30 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: G-protein-coupled receptors constitute the most diverse and largest receptor family in the human genome, with approximately 800 different members identified. Given the well-known metabolic alterations in cancer development, we will focus specifically in the 19 G-protein-coupled receptors (GPCRs), which can be selectively activated by metabolites. These metabolite sensing GPCRs control crucial processes, such as cell proliferation, differentiation, migration, and survival after their activation. In the present review, we will describe the main functions of these metabolite sensing GPCRs and shed light on the benefits of their potential use as possible pharmacological targets for cancer treatment. Keywords: G-protein-coupled receptor; metabolite sensing GPCR; cancer 1. Introduction G-protein-coupled receptors (GPCRs) are characterized by a seven-transmembrane configuration, constitute the largest and most ubiquitous family of plasma membrane receptors, and regulate virtually all known physiological processes in humans [1,2]. This family includes almost one thousand genes that were initially classified on the basis of sequence homology into six classes (A–F), where classes D and E were not found in vertebrates [3].
    [Show full text]
  • G Protein-Coupled Receptors in Stem Cell Maintenance and Somatic Reprogramming to Pluripotent Or Cancer Stem Cells
    BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-14-250 Title: G protein-coupled receptors in stem cell maintenance and somatic reprogramming to pluripotent or cancer stem cells Article Type: Mini Review Keywords: G protein-coupled receptors; stem cell maintenance; somatic reprogramming; cancer stem cells; pluripotent stem cell Corresponding Author: Ssang-Goo Cho Authors: Ssang-Goo Cho1,*, Hye Yeon Choi1, Subbroto Kumar Saha1, Kyeongseok Kim1, Sangsu Kim1, Gwang-Mo Yang1, BongWoo Kim1, Jin-hoi Kim1 Institution: 1Department of Animal Biotechnology, Animal Resources Research Center, and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea, UNCORRECTED PROOF 1 G protein-coupled receptors in stem cell maintenance and somatic reprogramming to 2 pluripotent or cancer stem cells 3 4 Hye Yeon Choi, Subbroto Kumar Saha, Kyeongseok Kim, Sangsu Kim, Gwang-Mo 5 Yang, BongWoo Kim, Jin-hoi Kim, and Ssang-Goo Cho 6 7 Department of Animal Biotechnology, Animal Resources Research Center, and 8 Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 9 120 Neungdong-ro, Gwangjin-gu, Seoul 143-701, Republic of Korea 10 * 11 Address correspondence to Ssang-Goo Cho, Department of Animal Biotechnology and 12 Animal Resources Research Center. Konkuk University, 120 Neungdong-ro, Gwangjin- 13 gu, Seoul 143-701, Republic of Korea. Tel: 82-2-450-4207, Fax: 82-2-450-1044, E-mail: 14 [email protected] 15 16 17 18 19 1 UNCORRECTED PROOF 20 Abstract 21 The G protein-coupled receptors (GPCRs) compose the third largest gene family in the 22 human genome, representing more than 800 distinct genes and 3–5% of the human genome.
    [Show full text]
  • Label-Free Cell Phenotypic Profiling Decodes the Composition And
    OPEN Label-free cell phenotypic profiling SUBJECT AREAS: decodes the composition and signaling POTASSIUM CHANNELS SENSORS AND PROBES of an endogenous ATP-sensitive Received potassium channel 28 January 2014 Haiyan Sun1*, Ying Wei1, Huayun Deng1, Qiaojie Xiong2{, Min Li2, Joydeep Lahiri1 & Ye Fang1 Accepted 24 April 2014 1Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States of Published America, 2The Solomon H. Snyder Department of Neuroscience and High Throughput Biology Center, Johns Hopkins University 12 May 2014 School of Medicine, Baltimore, Maryland 21205, United States of America. Current technologies for studying ion channels are fundamentally limited because of their inability to Correspondence and functionally link ion channel activity to cellular pathways. Herein, we report the use of label-free cell requests for materials phenotypic profiling to decode the composition and signaling of an endogenous ATP-sensitive potassium should be addressed to ion channel (KATP) in HepG2C3A, a hepatocellular carcinoma cell line. Label-free cell phenotypic agonist Y.F. (fangy2@corning. profiling showed that pinacidil triggered characteristically similar dynamic mass redistribution (DMR) com) signals in A431, A549, HT29 and HepG2C3A, but not in HepG2 cells. Reverse transcriptase PCR, RNAi knockdown, and KATP blocker profiling showed that the pinacidil DMR is due to the activation of SUR2/ Kir6.2 KATP channels in HepG2C3A cells. Kinase inhibition and RNAi knockdown showed that the pinacidil * Current address: activated KATP channels trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling. The results are the first demonstration of a label-free methodology to characterize the Biodesign Institute, composition and signaling of an endogenous ATP-sensitive potassium ion channel.
    [Show full text]
  • G Protein-Coupled Receptor 35: an Emerging Target in Inflammatory and Cardiovascular Disease
    Divorty, N., Mackenzie, A., Nicklin, S., and Milligan, G. (2015) G protein- coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Frontiers in Pharmacology, 6, 41. Copyright © 2015 The Authors. This work is made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0) Version: Published http://eprints.gla.ac.uk/106259/ Deposited on: 19 May 2015 Enlighten – Research publications by members of the University of Glasgow http://eprints.gla.ac.uk REVIEW ARTICLE published: 10 March 2015 doi: 10.3389/fphar.2015.00041 G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease Nina Divorty1,2 †, Amanda E. Mackenzie1†, Stuart A. Nicklin 2 and Graeme Milligan1* 1 Molecular Pharmacology Group, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK 2 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK Edited by: G protein-coupled receptor 35 (GPR35) is an orphan receptor, discovered in 1998, that has Terry Kenakin, University of North garnered interest as a potential therapeutic target through its association with a range of Carolina at Chapel Hill, USA diseases. However, a lack of pharmacological tools and the absence of convincingly defined Reviewed by: endogenous ligands have hampered the understanding of function necessary to exploit it Domenico Criscuolo, Genovax, Italy J. M. Ad Sitsen, ClinPharMed, therapeutically. Although several endogenous molecules can activate GPR35 none has yet Netherlands been confirmed as the key endogenous ligand due to reasons that include lack of biological *Correspondence: specificity, non-physiologically relevant potency and species ortholog selectivity.
    [Show full text]
  • Integrated Approaches for Genome-Wide Interrogation of The
    MINIREVIEW THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 32, pp. 19471–19477, August 7, 2015 © 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. 5-HT serotonin receptor agonism have long been docu- Integrated Approaches for 2B mented to induce severe, life-threatening valvular heart disease Genome-wide Interrogation of (6–8). Indeed, based on the potent 5-HT2B agonist activity of the Druggable Non-olfactory G certain ergot derivatives used in treating Parkinson disease and migraine headaches (e.g. pergolide, cabergoline, and dihydroer- Protein-coupled Receptor gotamine), we correctly predicted that these medications * would also induce valvular heart disease (7, 8). Two of these Superfamily drugs (pergolide and cabergoline) were withdrawn from the Published, JBC Papers in Press, June 22, 2015, DOI 10.1074/jbc.R115.654764 Bryan L. Roth1 and Wesley K. Kroeze international market following large-scale trials demonstrating From the Department of Pharmacology, University of North Carolina their life-threating side effects (8, 9). In follow-up studies, we Chapel Hill School of Medicine, Chapel Hill, North Carolina 27514 surveyed 2200 FDA-approved and investigational medications, finding that 27 had potentially significant 5-HT2B agonism, of G-protein-coupled receptors (GPCRs) are frequent and fruit- which 6 are currently FDA-approved (guanfacine, quinidine, ful targets for drug discovery and development, as well as being xylometazoline, oxymetazoline, fenoldopam, and ropinirole) off-targets for the side effects of a variety of medications. Much (10). Interestingly, of the 2200 drugs screened, around 30% dis- of the druggable non-olfactory human GPCR-ome remains played significant 5-HT2B antagonist activity (10), indicating under-interrogated, and we present here various approaches that 5-HT2B receptors represent a “promiscuous target” for that we and others have used to shine light into these previously approved and candidate medications.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Agonist-Induced Formation of Unproductive Receptor-G12 Complexes Najeah Okashaha, Shane C
    Agonist-induced formation of unproductive receptor-G12 complexes Najeah Okashaha, Shane C. Wrightb, Kouki Kawakamic, Signe Mathiasend,e,f, Joris Zhoub, Sumin Lua, Jonathan A. Javitchd,e,f, Asuka Inouec, Michel Bouvierb, and Nevin A. Lamberta,1 aDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912; bInstitute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; cGraduate School of Pharmaceutical Sciences, Tohoku University, 980-8578 Sendai, Japan; dDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032; eDepartment of Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032; and fDivision of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032 Edited by Brian K. Kobilka, Stanford University School of Medicine, Stanford, CA, and approved July 24, 2020 (received for review February 28, 2020) G proteins are activated when they associate with G protein- association does not always promote G protein activation and coupled receptors (GPCRs), often in response to agonist-mediated may in some circumstances inhibit downstream signaling. receptor activation. It is generally thought that agonist-induced receptor-G protein association necessarily promotes G protein acti- Results vation and, conversely, that activated GPCRs do not interact with V2R Interacts with G12 Heterotrimers. Conventional GPCR-G pro- G proteins that they do not activate. Here we show that GPCRs can tein coupling is understood as an allosteric interaction where an form agonist-dependent complexes with G proteins that they do agonist-bound active receptor mediates GDP release by stabi- not activate.
    [Show full text]
  • Protective Effect of Lodoxamide on Hepatic Steatosis Through GPR35 T ⁎ So-Yeon Nam, Soo-Jin Park, Dong-Soon Im
    Cellular Signalling 53 (2019) 190–200 Contents lists available at ScienceDirect Cellular Signalling journal homepage: www.elsevier.com/locate/cellsig Protective effect of lodoxamide on hepatic steatosis through GPR35 T ⁎ So-Yeon Nam, Soo-Jin Park, Dong-Soon Im College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Although GPR35 is an orphan G protein-coupled receptor, synthetic agonists and antagonists have been de- GPR35 veloped. Recently, cromolyn, a mast cell stabilizer, was reported as an agonist of GPR35 and was shown to Steatosis exhibit antifibrotic effects through its actions on hepatocytes and stellate cells. In this study, the roleofGPR35in Lodoxamide hepatic steatosis was investigated using an in vitro model of liver X receptor (LXR)-mediated hepatocellular Hepatocyte steatosis and an in vivo model of high fat diet-induced liver steatosis. GPR35 was expressed in Hep3B human Fatty liver hepatoma cells and mouse primary hepatocytes. A specific LXR activator, T0901317, induced lipid accumulation GPCR in Hep3B cells. Lodoxamide, the most potent agonist of GPR35, inhibited lipid accumulation in a concentration- dependent manner. The protective effect of lodoxamide was inhibited by a specific GPR35 antagonist, CID2745687, and by siRNA-mediated knockdown of GPR35. The expression of SREBP-1c, a key transcription factor for lipid synthesis, was induced by T0901317 and the induction was inhibited by lodoxamide. Through the use of specific inhibitors of cellular signaling components, the lodoxamide-induced inhibition of lipid accu- mulation was found to be mediated through p38 MAPKs and JNK, but not through Gi/o proteins and ERKs. Furthermore, the protective effect of lodoxamide was confirmed in mouse primary hepatocytes.
    [Show full text]
  • G Protein-Coupled Receptors
    Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences,
    [Show full text]
  • The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine
    International Journal of Molecular Sciences Review The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine Ning Liu 1,2,3,† , Shiqiang Sun 4,5,†, Pengjie Wang 2,3 , Yanan Sun 2,3, Qingjuan Hu 2,3 and Xiaoyu Wang 1,* 1 Key Laboratory of Precision Nutrition and Food Quality, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China; [email protected] 2 Department of Nutrition and Health, China Agricultural University, Beijing 100193, China; [email protected] (P.W.); [email protected] (Y.S.); [email protected] (Q.H.) 3 Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing 100193, China 4 Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713ZG Groningen, The Netherlands; [email protected] 5 Department of Genetics, University Medical Center Groningen, University of Groningen, 9713ZG Groningen, The Netherlands * Correspondence: [email protected]; Tel.: +86-10-6273-8589 † These authors contributed equally to this work. Abstract: Serotonin, also known as 5-hydroxytryptamine (5-HT), is a metabolite of tryptophan and is reported to modulate the development and neurogenesis of the enteric nervous system, gut motility, secretion, inflammation, sensation, and epithelial development. Approximately 95% of 5-HT in the body is synthesized and secreted by enterochromaffin (EC) cells, the most common type of neuroendocrine cells in the gastrointestinal (GI) tract, through sensing signals from the intestinal lumen and the circulatory system. Gut microbiota, nutrients, and hormones are the Citation: Liu, N.; Sun, S.; Wang, P.; main factors that play a vital role in regulating 5-HT secretion by EC cells.
    [Show full text]